92. The Tn3 scaffold of claim 89, wherein CD40L amino acids R203 and I204 are located in a first CD40L molecule, and CD40L amino acids V247, H249, and T251 are located in a second CD40L molecule.

93. An isolated nucleic acid molecule encoding a Tn3 scaffold of any one of the preceding claims.

94. An expression vector comprising the nucleic acid of claim 93.

95. A host cell comprising the vector of claim 94.

96. A method of producing a Tn3 scaffold comprising culturing the host cell of claim 95 under conditions in which the Tn3 scaffold encoded by the nucleic acid molecule is expressed.

97. A composition comprising a Tn3 scaffold of any one of the preceding claims and a pharmaceutically acceptable excipient.

98. Use of an effective amount of a composition of claim 96 in the manufacture of a medicament for ~~A method of~~ preventing, treating, ameliorating, or managing autoimmune disease in a patient in need thereof ~~comprising administering an effective amount of a composition of claim 96~~.

99. Use of a therapeutically effective amount of the composition of claim 93 in the manufacture of a medicament for ~~A method of~~ reducing the frequency or quantity of corticosteroid administered to a patient with an autoimmune disease ~~comprising administering to the patient a therapeutically effective amount of the composition of claim 93~~.

100. The use~~method~~ of any one of claims 98 or 99, wherein the autoimmune disease is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, Sjogren's syndrome, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, and chronic inflammation, sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis (e.g., psoriatic arthritis), anaphylactic shock, organ ischemia, reperfusion injury, spinal cord injury

and allograft rejection. autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychrondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynauld's phenomenon, Reiter's syndrome, Rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, lupus erythematosus, takayasu arteritis, temporal arteristis/giant cell arteritis, ulcerative colitis, uveitis, vasculitides such as dermatitis herpetiformis vasculitis, vitiligo, and Wegener's granulomatosis.

101. The use~~method~~ of any one of claims 98 or 99, wherein the autoimmune disease is Systemic Lupus Erythematosus (SLE).

102. The use~~method~~ of any one of claims 98 or 99, wherein said use~~method~~ further comprises an additional therapy, wherein said therapy is immunotherapy, biological therapy, chemotherapy, radiation therapy, or small molecule drug therapy.

103. A protein crystal comprising a Tn3 scaffold consisting of SEQ ID NO: 20 in a complex with soluble CD40L (SEQ ID NO: 2) wherein the crystal has a crystal lattice in a $P2_12_12_1$ orthorhombic space group and unit cell dimensions, +/- 0.1%, of a=85.69 Å , b=90.64 Å , c=95.56 Å.

104. The protein crystal of claim 103, wherein the asymmetric unit of the crystal comprises a trimer of CD40L and three molecules of Tn3 scaffold.